Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy
Abstract In recent years, immunotherapy has become a standard cancer therapy, joining surgery, chemotherapy, and radiation therapy. This therapeutic approach involves the use of patient-derived antigen-specific T cells or genetically modified T cells engineered with chimeric antigen receptors (CAR)...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-04-01
|
| Series: | Inflammation and Regeneration |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41232-024-00328-3 |
| _version_ | 1827277315269197824 |
|---|---|
| author | Sota Kurihara Akihiro Ishikawa Shin Kaneko |
| author_facet | Sota Kurihara Akihiro Ishikawa Shin Kaneko |
| author_sort | Sota Kurihara |
| collection | DOAJ |
| description | Abstract In recent years, immunotherapy has become a standard cancer therapy, joining surgery, chemotherapy, and radiation therapy. This therapeutic approach involves the use of patient-derived antigen-specific T cells or genetically modified T cells engineered with chimeric antigen receptors (CAR) or T cell receptors (TCR) that specifically target cancer antigens. However, T cells require ex vivo stimulation for proliferation when used in therapy, and the resulting “exhaustion,” which is characterized by a diminished proliferation capacity and anti-tumor activity, poses a significant challenge. As a solution, we reported “rejuvenated” CD8 + T cells that possess high proliferation capacity from induced pluripotent stem cells (iPSCs) in 2013. This review discusses the status and future developments in immunotherapy using iPSC-derived T cells, drawing insights from our research to overcome the exhaustion associated with antigen-specific T cell therapy. |
| first_indexed | 2024-04-24T07:18:50Z |
| format | Article |
| id | doaj.art-c0a29fa56c4f4049a79a6eb4603f6a03 |
| institution | Directory Open Access Journal |
| issn | 1880-8190 |
| language | English |
| last_indexed | 2024-04-24T07:18:50Z |
| publishDate | 2024-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Inflammation and Regeneration |
| spelling | doaj.art-c0a29fa56c4f4049a79a6eb4603f6a032024-04-21T11:12:07ZengBMCInflammation and Regeneration1880-81902024-04-014411810.1186/s41232-024-00328-3Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapySota Kurihara0Akihiro Ishikawa1Shin Kaneko2Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto UniversityShin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto UniversityShin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto UniversityAbstract In recent years, immunotherapy has become a standard cancer therapy, joining surgery, chemotherapy, and radiation therapy. This therapeutic approach involves the use of patient-derived antigen-specific T cells or genetically modified T cells engineered with chimeric antigen receptors (CAR) or T cell receptors (TCR) that specifically target cancer antigens. However, T cells require ex vivo stimulation for proliferation when used in therapy, and the resulting “exhaustion,” which is characterized by a diminished proliferation capacity and anti-tumor activity, poses a significant challenge. As a solution, we reported “rejuvenated” CD8 + T cells that possess high proliferation capacity from induced pluripotent stem cells (iPSCs) in 2013. This review discusses the status and future developments in immunotherapy using iPSC-derived T cells, drawing insights from our research to overcome the exhaustion associated with antigen-specific T cell therapy.https://doi.org/10.1186/s41232-024-00328-3CD8 + T cellChimeric antigen receptorGenome editingImmunotherapyiPSC |
| spellingShingle | Sota Kurihara Akihiro Ishikawa Shin Kaneko Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy Inflammation and Regeneration CD8 + T cell Chimeric antigen receptor Genome editing Immunotherapy iPSC |
| title | Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy |
| title_full | Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy |
| title_fullStr | Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy |
| title_full_unstemmed | Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy |
| title_short | Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy |
| title_sort | genome editing ipsc to purposing enhancement of induce cd8 killer t cell function for regenerative immunotherapy |
| topic | CD8 + T cell Chimeric antigen receptor Genome editing Immunotherapy iPSC |
| url | https://doi.org/10.1186/s41232-024-00328-3 |
| work_keys_str_mv | AT sotakurihara genomeeditingipsctopurposingenhancementofinducecd8killertcellfunctionforregenerativeimmunotherapy AT akihiroishikawa genomeeditingipsctopurposingenhancementofinducecd8killertcellfunctionforregenerativeimmunotherapy AT shinkaneko genomeeditingipsctopurposingenhancementofinducecd8killertcellfunctionforregenerativeimmunotherapy |